Open-label randomized non-inferiority trial of a fixed-dose combination of glimepiride and atorvastatin for the treatment of people whose Type 2 diabetes is uncontrolled on metformin-Reference-Cited by-同舟云学术

Open-label randomized non-inferiority trial of a fixed-dose combination of glimepiride and atorvastatin for the treatment of people whose Type 2 diabetes is uncontrolled on metformin

Published:2015-12-12 Issue:8 Volume:33 Page:1084-1093
ISSN:0742-3071
Container-title:Diabetic Medicine
language:en
Short-container-title:Diabet. Med.

Author:

Ambery P.¹,Stylianou A.²,Atkinson G.³,Dott C.³,Baylor Curtis L.³,Haque N.³,LaCroix K.⁴,Min K. W.⁵,

Affiliation:

1. Department of Medicine; Addenbrooke's Hospital; Cambridge UK

2. Clinical Statistics; GlaxoSmithKline; Stevenage UK

3. Alternative Discovery and Development; GlaxoSmithKline; Brentford UK

4. Global Clinical Safety and Pharmacovigilance; GlaxoSmithKline; Research Triangle Park NC USA

5. Diabetes Centre; Eulji Hospital; Eulji University School of Medicine; Seoul Republic of Korea

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dme.13003/fullpdf

Reference26 articles.

1. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Inzucchi;Diabetologia,2012

2. Intensive glucose lowering and cardiovascular disease prevention in diabetes: reconciling the recent clinical trial data;Mazzone;Circulation,2010

3. Dyslipidemia in type 2 diabetes mellitus;Mooradian;Nat Clin Pract Endocrinol Metab,2009

4. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines;Stone;Circulation,2014

5. National Institute for Health and Care Excellence Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease [Guideline CG181] 2014 https://www.nice.org.uk/guidance/cg181/resources/guidance-lipid-modification-cardiovascular-risk-assessment-and-the-modification-of-blood-lipids-for-the-primary-and-secondary-prevention-of-cardiovascular-disease-pdf

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of Single-Tablet Combination Therapy in Improving Adherence and Persistence and the Relation to Clinical and Economic Outcomes;Journal of Health Economics and Outcomes Research;2024-01-23

2. Effectiveness of Single-Tablet Combination Therapy in Improving Adherence and Persistence and the Relation to Clinical and Economic Outcomes;Journal of Health Economics and Outcomes Research;2024

3. Efficacy and safety of xuezhikang once per day versus two times per day in patients with mild to moderate hypercholesterolaemia (APEX study): a protocol for a multicentre, prospective randomised controlled, open-label, non-inferiority study;BMJ Open;2020-05